Contrive Datum Insights has published "Hereditary Angioedema Market Size, Share & Industry Analysis, By Type (C1 Esterase Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Others), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Treatment type (Prophylactic Therapy, On-demand (Acute) Treatment), Route of administration (Subcutaneous, Intravenous, Oral), End user (Hospitals, Specialty Clinics, Homecare / Self-Administration), and Regional Forecast, 2026-2034". The study sizes the global hereditary angioedema market at USD 3.75 billion in 2025 and projects growth from USD 4.08 billion in 2026 to USD 7.15 billion by 2034, a compound annual growth rate of 7.27% across the forecast period.
Hereditary angioedema therapeutics are the prescription drug products used to prevent and treat acute swelling attacks caused by hereditary angioedema, delivered as intravenous or subcutaneous biologics or, increasingly, as oral medicines. Buyers are prescribing physicians, hospital and specialty pharmacies, and the patients and caregivers who administer maintenance or on-demand doses, working within health systems and payers that determine which therapies are reimbursed.
Expanding prophylactic biologic uptake
Expanding prophylactic biologic uptake is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 7.27% a year, the type lines exposed to it move fastest: Kallikrein Inhibitor compounds at 10.93%, taking its share of revenue from 17.6% to 24.06% and its value from USD 0.66 billion to USD 1.72 billion.
On the upside, the study's bull case assumes bull case assumes faster physician adoption of new oral prophylactic therapies and broader reimbursement expansion into additional national health systems, which would take 2034 revenue to USD 8.22 billion rather than the USD 7.15 billion base case.
However, bear case assumes slower diagnosis growth, continued payer pricing pressure, and delayed reimbursement approvals for newer oral therapies in several regions, which would hold 2034 revenue to USD 6.08 billion. C1 Esterase Inhibitor, which carries 62.4% of 2025 revenue, already grows at only 5.15% against the market's 7.27%, so the largest part of the base is also its slowest.
Key Players Compete on C1 Esterase Inhibitor Volume and Kallikrein Inhibitor Growth
Competition in the global hereditary angioedema market runs along the type axis rather than the regional one. C1 Esterase Inhibitor holds 62.4% of 2025 revenue at USD 2.34 billion and remains the largest line through 2034 at 52.03%, making it the position hardest for a challenger to take. Kallikrein Inhibitor, growing at 10.93%, is where share actually changes hands. A supplier established in one is not thereby established in the other, which is what sustains a field of this size in a market of USD 3.75 billion.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Type | C1 Esterase Inhibitor | 62.4% · USD 2.34 billion | — |
| Application | Hospital Pharmacies | 46.93% · USD 1.76 billion | Online Pharmacies 12.22% |
| Treatment type | Prophylactic Therapy | 58.13% · USD 2.18 billion | — |
| Route of administration | Subcutaneous | 45.07% · USD 1.69 billion | Oral 13.21% |
| End user | Hospitals | 40% · USD 1.5 billion | Homecare / Self-Administration 10.59% |
- Based on regional analysis, North America led the global hereditary angioedema market in 2025 with 50.21% of global revenue at USD 1.88 billion, reaching USD 3.36 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 14.79% in 2025 to 18% in 2034, with revenue growing from USD 0.56 billion to USD 1.29 billion.
- Middle East and Africa remains the smallest region throughout, at 3.36% of 2025 revenue and 4% by 2034.
- Kallikrein Inhibitor is projected to grow at 10.93% over the forecast period, the fastest of any type line.
- The United States is the largest single country market at USD 1.69 billion in 2025, 45.07% of global revenue.
The report segments the market across five axes; by type, and by application, treatment type, route of administration and end user; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 6.08 billion and USD 8.22 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.